Amizon

Enisamium (40-1000 μM; 24 h) dose-dependently reduces replication of multiple influenza A (including oseltamivir-resistant influenza A^H275Y mutant) and B viruses in differentiated NHBE cells, with the greatest reduction of 2.8 log₁₀TCID₅₀/mL observed at 1000 μM for 24 hours against influenza A/TN/1-560/09 [H1N1]^[1].
Enisamium (500-1000 μM; 24-48 h) significantly reduces replication of influenza A/Brisbane/59/2007 (H1N1) virus in differentiated NHBE cells at MOIs of 0.01, 0.001, and 0.0001 PFU/cell when administered post-infection^[1].
Enisamium (10-1000 μM; 24 h) exhibits low permeability (1.1-1.6%) across differentiated NHBE cells after 24 hours of exposure at 10-1000 μM, with intracellular concentrations increasing in a dose-dependent manner^[1].
Enisamium (2000 μM; total 24 h) significantly reduces replication and matrix gene expression of influenza A/Brisbane/59/2007 (H1N1) virus in differentiated NHBE cells when added between 1 hour before and 10 hours after viral inoculation for a total 24-hour incubation^[1].
Enisamium (100-1000 μM; 24 h pre-incubation, maintained throughout) significantly reduces replication of influenza A/Brisbane/59/2007 (H1N1) virus in differentiated NHBE cells over 24 and 48 hours post-inoculation^[1].
Enisamium iodide (10-100 μM; 48 h) inhibits mRNA expression of pro-inflammatory mediators (COX-1, COX-2, NF-κB, TGF1β, IL-1, IL-6) and increases anti-inflammatory IL-10 mRNA expression in phytohemagglutinin-stimulated human PBMC, with 10 μM reducing target pro-inflammatory gene expression by up to 67% and increasing IL-10 expression by 73%^[2].
Enisamium iodide (50 μM; 72 h) stimulates secretion of the anti-inflammatory cytokine IL-10 by 1.5-fold with statistical significance in phytohemagglutinin-stimulated human PBMC^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.